MOUNTAIN VIEW, Calif., June 25, 2013 /PRNewswire/ -- Best-selling drugs with a combined worth of $73.85 billion that include Lipitor, Actos and Plavix are expected to lose patent protection in the United States by 2017. As a result, an influx of generic manufacturers and an increased volume of new drugs is expected in the market, thus sustaining the demand for oral solid drug dosage excipients in North America. These inert substances serve as vehicles for active ingredients in drugs and include binders and fillers, disintegrants, coatings, flavors, colors, sweeteners, glidants, adhesives and lubricants.
New analysis from Frost & Sullivan (http://www.chemicals.frost.com), Analysis of the North American Oral Solid Drug Dosage Excipients Market, finds that the market earned revenue of $1.19 billion in 2012 and estimates this to reach $1.70 billion in 2019 at a compound annual growth rate of 5.4 percent.
If you are interested in more information on this research, please send an e-mail to Jeannette Garcia, Corporate Communications, at email@example.com, with your full name, company name, job title, telephone number, company e-mail address, company website, city, state and country.
"The need to improve drug manufacturing processes and the quality of drug formulations has led to the production of multi-functional excipients with better manufacturing accuracy and purity," said Frost & Sullivan Chemicals, Materials and Food Industry Analyst Dr. Nandhini Rajagopal, Ph.D. "The upcoming cost-effective tablet processing method, in particular, will require excipients with excellent functionalities and improved physical and chemical properties."
Cost containment efforts by the government and healthcare providers have further escalated the import of generic drugs to the United States, resulting in price erosion and reduced margins for domestic excipient vendors.
Manufacturers can overcome price restraints by shifting their production facilities to less costly regions such as Asia. Also, due to stringent regulations and intense competition, it is also essential for companies to invest in research and development to benefit in the long run.
"Excipient suppliers in North America have focused on high-margin segments, such as coating polymers, co-processed excipients, coating systems and super disintegrants to boost their profit. However, the expensive nature of drugs and low-cost competition from emerging markets may restrict the overall drug manufacturing market in the country," added Frost & Sullivan Vice President of Chemicals, Materials and Food Growth Consulting Shomik Majumdar.
Analysis of the North American Oral Solid Drug Dosage Excipients Market is part of the Chemicals & Materials Growth Partnership Service program. Frost & Sullivan's related research services cover the Chinese pharmaceutical excipient market. All research services included in subscriptions provide detailed market opportunities and industry trends evaluated following extensive interviews with market participants.
About Frost & Sullivan
Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today's market participants.
Our "Growth Partnership" supports clients by addressing these opportunities and incorporating two key elements driving visionary innovation: The Integrated Value Proposition and The Partnership Infrastructure.
For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Is your organization prepared for the next profound wave of industry convergence, disruptive technologies, increasing competitive intensity, Mega Trends, breakthrough best practices, changing customer dynamics and emerging economies?
Analysis of the North American Oral Solid Drug Dosage Excipients Market
Contact: Jeannette Garcia
Corporate Communications – North America
Linkedin: Future of Chemicals- A Frost & Sullivan Forum
|SOURCE Frost & Sullivan|
Copyright©2012 PR Newswire.
All rights reserved